GO
Loading...

Amylin Pharmaceuticals

  • $7.1 Billion Pharma Deal  Monday, 2 Jul 2012 | 1:11 PM ET

    CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.

  • What's Next for Carl Icahn?  Monday, 30 Apr 2012 | 4:14 PM ET

    CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.

  • Icahn to Buy CVR Energy with Shareholder Support  Tuesday, 3 Apr 2012 | 5:16 PM ET

    Carl Icahn, Icahn Enterprises chairman, discusses his tender offer for CVR Energy, and now holds 69% of the company's shares. Icahn also weighs in on whether Amylin Pharma should be sold, and reveals his thoughts on RIMM, with the Fast Money traders.

  • Amylin CEO on Exenatide  Tuesday, 8 Nov 2011 | 5:53 PM ET

    Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.